Insmed, Inc. Hits 52-Week Low at $90.41 Amid Market Volatility

Insmed, Inc., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has recently reached a new 52-week low of USD 90.41 on June 10, 2026. This significant decline highlights the stock's volatility, especially when compared to its 52-week high of USD 212.75. Over the past year, Insmed has demonstrated a performance of 53.39%, which notably outpaces the S&P 500's performance of 20.34%. Despite this positive annual performance, the current low price reflects underlying market dynamics that may be influencing investor sentiment. Financial metrics reveal that Insmed operates with a market capitalization of USD 31,320 million. The company is currently loss-making, as indicated by its negative price-to-earnings ratio and a return on equity of -138.68%. Additionally, the company has a price-to-book ratio of 42.38, and it does not offer a dividend yield. The debt-to-equity ratio stands at -0.96, suggesting a unique financial structure. As the stock navigates these challenges, its recent price movement underscores the complexities within the biotechnology landscape.